Recombinant Antibodies for Pathogen Detection and Immunotherapy

Handbook of Pharmaceutical Biotechnology

Volumn , Issue , 2006, Pages 851-881

  Pokorny, Nicholas J ^a   Boulter Bitzer, Jeanine I ^a   Hall, J Chris ^a   Trevors, Jack T ^a   Lee, Hung ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

Pathogen detection and immunotherapy; Pathogen immunodetection

Indexed keywords

EID: 84889809845     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470117118.ch06f     Document Type: Chapter

References (160)

1. Kohler G, Milstein C (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:495-497.
2. Holliger P, Hudson P J (2005). Engineered antibody fragments and the rise of single domains. Nature Biotechnol. 23:1126-1136.
3. Goldsby R A, Kindt T J, Osborne B A, et al. (2003). Immunology. W.H. Freeman, New York.
4. Stanfield R L, Takimoto-Kamimura M, Rini J M, et al. (1993). Major antigen-induced domain rearrangements in an antibody. Structure. 1:83-93.
5. Hoogenboom H R, Winter G (1992). By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J. Mol. Biol. 227:381-388.
6. Berry J D (2005). Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: The antigen scale. Vet. J. 170:193-211.
7. Yau K Y, Lee H, Hall J C (2003). Emerging trends in the synthesis and improvement of hapten-specific recombinant antibodies. Biotechnol. Adv. 21:599-637.
8. Thullier P, Lafaye P, Megret F, et al. (1999). A recombinant Fab neutralizes dengue virus in vitro. J. Biotechnol. 69:183-190.
9. Park K J, Park D W, Kim C H, et al. (2005). Development and characterization of a recombinant chicken single-chain Fv antibody detecting Eimeria acervulina sporozoite antigen. Biotechnol. Lett. 27:289-295.
10. Ward E S, Gussow D, Griffiths A D, et al. (1989). Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature. 341:544-546.
11. van der Linden R H, Frenken L G, de Geus B, et al. (1999). Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim. Biophys. Acta. 1431:37-46.
12. Nuttall S D, Humberstone K S, Krishnan U V, et al. (2004). Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1. Proteins. 55:187-197.
13. Emanuel P A, Dang J, Gebhardt J S, et al. (2000). Recombinant antibodies: a new reagent for biological agent detection. Biosens. Bioelectron. 14:751-759.
14. Crowe J E, Jr, Cheung P Y, Wallace E F, et al. (1994). Isolation and characterization of a chimpanzee monoclonal antibody to the G glycoprotein of human respiratory syncytial virus. Clin. Diagn. Lab. Immunol. 1:701-706.
15. Lamarre A, Talbot P J (1995). Protection from lethal coronavirus infection by immunoglobulin fragments. J. Immunol. 154:3975-3984.
16. Whitlow M, Bell B A, Feng S L, et al. (1993). An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng. 6:989-995.
17. Lamarre A, Yu M W, Chagnon F, et al. (1997). A recombinant single chain antibody neutralizes coronavirus infectivity but only slightly delays lethal infection of mice. Eur. J. Immunol. 27:3447-3455.
18. Joosten V, Lokman C, Van Den Hondel C A, et al. (2003). The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. Microb. Cell Fact. 2:1-15.
19. Greenberg A S, Avila D, Hughes M, et al. (1995). A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature. 374:168-173.
20. Nuttall S D, Krishnan U V, Doughty L, et al. (2003). Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70. Eur. J. Biochem. 270:3543-3554.
21. Hudson P J, Kortt A A (1999). High avidity scFv multimers; diabodies and triabodies. J. Immunol. Meth. 231:177-189.
22. Zhang J, Tanha J, Hirama T, et al. (2004). Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents. J. Mol. Biol. 335:49-56.
23. Kim I S, Shim J H, Suh Y T, et al. (2002). Green fluorescent protein-labeled recombinant fluobody for detecting the picloram herbicide. Biosci. Biotechnol. Biochem. 66:1148-1151.
24. Benhar I (2001). Biotechnological applications of phage and cell display. Biotechnol. Adv. 19:1-33.
25. Krebber A, Bornhauser S, Burmester J, et al. (1997). Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J. Immunol. Meth. 201:35-55.
26. Siegel D L (2002). Recombinant monoclonal antibody technology. Transfus. Clin. Biol. 9:15-22.
27. Barbos C F III, Burton D R, Scott J K, et al. (2001). Phage Display: A Laboratory Manual. Cold Sprng Harbor Laboratory, Cold Spring Harbor, N.Y.
28. Feng J N, Russel M, Model P (1997). A permeabilized cell system that assembles filamentous bacteriophage. Proc. Natl. Acad. Sci. (USA). 94:4068-4073.
29. Fernandez L A (2004). Prokaryotic expression of antibodies and affibodies. Curr. Opin. Biotechnol. 15:364-373.
30. Iannolo G, Minenkova O, Petruzzelli R, et al. (1995). Modifying filamentous phage capsid: limits in the size of the major capsid protein. J. Mol. Biol. 248:835-844.
31. MacKenzie R, To R (1998). The role of valency in the selection of anti-carbohydrate single-chain Fvs from phage display libraries. J. Immunol. Meth. 220:39-49.
32. Tout N L, Yau K Y, Trevors J T, et al. (2001). Synthesis of ligand-specific phage-display ScFv against the herbicide picloram by direct cloning from hyperimmunized mouse. J. Agric. Food Chem. 49:3628-3637.
33. Rondot S, Koch J, Breitling F, et al. (2001). A helper phage to improve single-chain antibody presentation in phage display. Nature Biotechnol. 19:75-78.
34. Goletz S, Christensen P A, Kristensen P, et al. (2002). Selection of large diversities of antiidiotypic antibody fragments by phage display. J. Mol. Biol. 315:1087-1097.
35. O'Connell D, Becerril B, Roy-Burman A, et al. (2002). Phage versus phagemid libraries for generation of human monoclonal antibodies. J. Mol. Biol. 321:49-56.
36. Georgiou G, Poetschke H L, Stathopoulos C, et al. (1993). Practical applications of engineering gram-negative bacterial cell surfaces. Trends Biotechnol. 11:6-10.
37. Samuelson P, Gunneriusson E, Nygren P A, et al. (2002). Display of proteins on bacteria. J. Biotechnol. 96:129-154.
38. Charbit A, Wang J, Michel V, et al. (1998). A cluster of charged and aromatic residues in the C-terminal portion of maltoporin participates in sugar binding and uptake. Mol. Gen. Genet. 260:185-192.
39. Mejare M, Ljung S, Bulow L (1998). Selection of cadmium specific hexapeptides and their expression as OmpA fusion proteins in Escherichia coli. Protein Eng. 11:489-494.
40. Janssen R, Tommassen J (1994). PhoE protein as a carrier for foreign epitopes. Int. Rev. Immunol. 11:113-121.
41. Fuchs P, Breitling F, Dubel S, et al. (1991). Targeting recombinant antibodies to the surface of Escherichia coli: fusion to a peptidoglycan associated lipoprotein. BioTechnol. 9:1369-1372.
42. Fuchs P, Weichel W, Dubel S, et al. (1996). Separation of E. coli expressing functional cell-wall bound antibody fragments by FACS. Immunotechnol. 2:97-102.
43. Hedegaard L, Klemm P (1989). Type 1 fimbriae of Escherichia coli as carriers of heterologous antigenic sequences. Gene. 85:115-124.
44. Lu Z, Murray K S, Van Cleave V, et al. (1995). Expression of thioredoxin random peptide libraries on the Escherichia coli cell surface as functional fusions to flagellin:A system designed for exploring protein-protein interactions. BioTechnol. 13:366-372.
45. Kornacker M G, Pugsley A P (1990). The normally periplasmic enzyme betalactamase is specifically and efficiently translocated through the Escherichia coli outermembrane when it is fused to the cell-surface enzyme pullulanase. Mol. Microbiol. 4:1101-1109.
46. Francisco J A, Stathopoulos C, Warren R A, et al. (1993). Specific adhesion and hydrolysis of cellulose by intact Escherichia coli expressing surface anchored cellulase or cellulose binding domains. BioTechnol. 11:491-495.
47. Chen G, Cloud J, Georgiou G, et al. (1996). A quantitative immunoassay utilizing Escherichia coli cells possessing surface-expressed single chain Fv molecules. Biotechnol. Prog. 12:572-574.
48. Gunneriusson E, Samuelson P, Uhlen M, et al. (1996). Surface display of a functional single-chain Fv antibody on staphylococci. J. Bacteriol. 178:1341-1346.
49. Du C, Chan W C, McKeithan T W, et al. (2005). Surface display of recombinant proteins on Bacillus thuringiensis spores. Appl. Environ. Microbiol. 71:3337-3341.
50. Georgiou G, Stathopoulos C, Daugherty P S, et al. (1997). Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. Nature Biotechnol. 15:29-34.
51. Colby D W, Kellogg B A, Graff C P, et al. (2004). Engineering antibody affinity by yeast surface display. Methods Enzymol. 388:348-358.
52. Boder E T, Wittrup K D (2000). Yeast surface display for directed evolution of protein expression, affinity, and stability. Meth. Enzymol. 328:430-444.
53. Feldhaus M J, Siegel R W (2004). Yeast display of antibody fragments: a discovery and characterization platform. J. Immunol. Meth. 290:69-80.
54. Kieke M C, Cho B K, Boder E T, et al. (1997). Isolation of anti-T cell receptor scFv mutants by yeast surface display. Protein Eng. 10:1303-1310.
55. Washida M, Takahashi S, Ueda M, et al. (2001). Spacer-mediated display of active lipase on the yeast cell surface. Appl. Microbiol. Biotechnol. 56:681-686.
56. Kim S Y, Sohn J H, Pyun Y R, et al. (2002). A cell surface display system using novel GPI-anchored proteins in Hansenula polymorpha. Yeast. 19:1153-1163.
57. Matsumoto T, Fukuda H, Ueda M, et al. (2002). Construction of yeast strains with high cell surface lipase activity by using novel display systems based on the Flo1p flocculation functional domain. Appl. Environ. Microbiol. 68:4517-4522.
58. VanAntwerp J J, Wittrup K D (2000). Fine affinity discrimination by yeast surface display and flow cytometry. Biotechnol. Prog. 16:31-37.
59. He M, Taussig M J (1997). Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucl. Acids. Res. 25:5132-5134.
60. Hanes J, Jermutus L, Weber-Bornhauser S, et al. (1998). Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Proc. Natl. Acad. Sci. (USA). 95:14130-14135.
61. Hanes J, Schaffitzel C, Knappik A, et al. (2000). Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nature Biotechnol. 18:1287-1292.
62. Jermutus L, Honegger A, Schwesinger F, et al. (2001). Tailoring in vitro evolution for protein affinity or stability. Proc. Natl. Acad. Sci. (USA). 98:75-80.
63. Olea-Popelka F, McLean M D, Horsman J, et al. (2005). Increasing expression of an anti-picloram single-chain variable fragment (ScFv) antibody and resistance to picloram in transgenic tobacco (Nicotiana tabacum). J. Agric. Food Chem. 53:6683-6690.
64. Peipp M, Saul D, Barbin K, et al. (2004). Efficient eukaryotic expression of fluorescent scFv fusion proteins directed against CD antigens for FACS applications. J. Immunol. Meth. 285:265-280.
65. Kamihira M, Ono K, Esaka K, et al. (2005). High-level expression of single-chain Fv-Fc fusion protein in serum and egg white of genetically manipulated chickens by using a retroviral vector. J. Virol. 79:10864-10874.
66. Miller D N, Bryant J E, Madsen E L, et al. (1999). Evaluation and optimization of DNA extraction and purification procedures for soil and sediment samples. Appl. Environ. Microbiol. 65:4715-4724.
67. Zhou B, Wirsching P, Janda K D (2002). Human antibodies against spores of the genus Bacillus: a model study for detection of and protection against anthrax and the bioterrorist threat. Proc. Natl. Acad. Sci. (USA). 99:5241-5246.
68. Lim K P, Li H, Nathan S (2004). Expression and purification of a recombinant scFv towards the exotoxin of the pathogen, Burkholderia pseudomallei. J. Microbiol. 42:126-132.
69. Nathan S, Li H, Mohamed R, Embi N (2002). Phage display of recombinant antibodies toward Burkholderia pseudomallei exotoxin. J. Biochem. Mol. Biol. Biophys. 6:45-53.
70. Lindquist E A, Marks J D, Kleba B J, et al. (2002). Phage-display antibody detection of Chlamydia trachomatis-associated antigens. Microbiol. 148:443-451.
71. McElhiney J, Drever M, Lawton L A, et al. (2002). Rapid isolation of a single-chain antibody against the cyanobacterial toxin microcystin-LR by phage display and its use in the immunoaffinity concentration of microcystins from water. Appl. Environ. Microbiol. 68:5288-5295.
72. Deng X K, Nesbit L A, Morrow K J, Jr (2003). Recombinant single-chain variable fragment antibodies directed against Clostridium difficile toxin B produced by use of an optimized phage display system. Clin. Diagn. Lab. Immunol. 10:587-595.
73. Kanitpun R, Wagner G G, Waghela S D (2004). Characterization of recombinant antibodies developed for capturing enterohemorrhagic Escherichia coli O157:H7. Southeast Asian J. Trop. Med. Public Health. 35:902-912.
74. Boel E, Bootsma H, de Kruif J, et al. (1998). Phage antibodies obtained by competitive selection on complement-resistant Moraxella (Branhamella) catarrhalis recognize the high-molecular-weight outer membrane protein. Infect. Immun. 66:83-88.
75. Kuepper M B, Huhn M, Spiegel H, et al. (2005). Generation of human antibody fragments against Streptococcus mutans using a phage display chain shuffling approach. BMC Biotechnol. 5:1-12.
76. de Greeff A, van Alphen L, Smith H E (2000). Selection of recombinant antibodies specific for pathogenic Streptococcus suis by subtractive phage display. Infect. Immun. 68:3949-3955.
77. Haidaris C G, Malone J, Sherrill L A, et al. (2001). Recombinant human antibody single chain variable fragments reactive with Candida albicans surface antigens. J. Immunol. Meth. 257:185-202.
78. Choi G H, Lee D H, Min W K, et al. (2004). Cloning, expression, and characterization of single-chain variable fragment antibody against mycotoxin deoxynivalenol in recombinant Escherichia coli. Protein Expr. Purif. 35:84-92.
79. Gough K C, Li Y, Vaughan T J, et al. (1999). Selection of phage antibodies to surface epitopes of Phytophthora infestans. J. Immunol. Methods. 228:97-108.
80. Chen L, Williams B R, Yang C Y, et al. (2003). Polyclonal Fab phage display libraries with a high percentage of diverse clones to Cryptosporidium parvum glycoproteins. Int. J. Parasitol. 33:281-291.
81. Tachibana H, Cheng X J, Watanabe K, et al. (1999). Preparation of recombinant human monoclonal antibody Fab fragments specific for Entamoeba histolytica. Clin. Diagn. Lab. Immunol. 6:383-387.
82. Fu Y, Shearing L N, Haynes S, et al. (1997). Isolation from phage display libraries of single chain variable fragment antibodies that recognize conformational epitopes in the malaria vaccine candidate, apical membrane antigen-1. J. Biol. Chem. 272:25678-25684.
83. Kerschbaumer R J, Hirschl S, Kaufmann A, et al. (1997). Single-chain Fv fusion proteins suitable as coating and detecting reagents in a double antibody sandwich enzymelinked immunosorbent assay. Anal. Biochem. 249:219-227.
84. Nagesha H S, Wang L F, Shiell B, et al. (2001). A single chain Fv antibody displayed on phage surface recognises conformational group-specific epitope of bluetongue virus. J. Virol. Meth. 91:203-207.
85. Chae J S, Choi J K, Lim H T, et al. (2001). Generation of a murine single chain Fv (scFv) antibody specific for cucumber mosaic virus (CMV) using a phage display library. Mol. Cells. 11:7-12.
86. Maruyama T, Parren P W, Sanchez A, et al. (1999). Recombinant human monoclonal antibodies to Ebola virus. J. Infect. Dis. 179(suppl 1):S235-239.
87. ShengFeng C, Ping L, Tao S, et al. (2003). Construction, expression, purification, refold and activity assay of a specific scFv fragment against foot and mouth disease virus. Vet. Res. Commun. 27:243-256.
88. Saldarelli P, Keller H, Dell'Orco M, et al. (2005). Isolation of recombinant antibodies (scFvs) to grapevine virus B. J. Virol. Methods. 124:191-195.
89. Cattani P, Rossolini G M, Cresti S, et al. (1997). Detection and typing of herpes simplex viruses by using recombinant immunoglobulin fragments produced in bacteria. J. Clin. Microbiol. 35:1504-1509.
90. Bugli F, Manzara S, Torelli R, et al. (2004) Human monoclonal antibody fragment specific for glycoprotein G in herpes simplex virus type 2 with applications for serotype-specific diagnosis. J. Clin. Microbiol. 42:1250-1253.
91. Williamson R A, Lazzarotto T, Sanna P P, et al. (1997). Use of recombinant human antibody fragments for detection of cytomegalovirus antigenemia. J. Clin. Microbiol. 35:2047-2050.
92. Sapats S I, Heine H G, Trinidad L, et al. (2003). Generation of chicken single chain antibody variable fragments (scFv) that differentiate and neutralize infectious bursal disease virus (IBDV). Arch. Virol. 148:497-515.
93. Desogus A, Burioni R, Ingianni A, et al. (2003). Production and characterization of a human recombinant monoclonal Fab fragment specific for influenza A viruses. Clin. Diagn. Lab. Immunol. 10:680-685.
94. Liu H, Ding Y L, Han W, Liu M Y, et al. (2004). Recombinant scFv antibodies against E protein and N protein of severe acute respiratory syndrome virus. Acta Biochim. Biophys. Sin. 36:541-547.
95. Schmaljohn C, Cui Y, Kerby S, et al. (1999). Production and characterization of human monoclonal antibody Fab fragments to vaccinia virus from a phage-display combinatorial library. Virol. 258:189-200.
96. Duggan J M, Coates D M, Ulaeto D O (2001). Isolation of single-chain antibody fragments against Venezuelan equine encephalomyelitis virus from two different immune sources. Viral Immunol. 14:263-273.
97. Hu W G, Alvi A Z, Chau D, et al. (2003). Development and characterization of a novel fusion protein composed of a human IgG1 heavy chain constant region and a single-chain fragment variable antibody against Venezuelan equine encephalitis virus. J. Biochem. 133:59-66.
98. Cardinale A, Filesi I, Vetrugno V, et al. (2005). Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc accumulation. J. Biol. Chem. 280:685-694.
99. Devaux C, Moreau E, Goyffon M, et al. (2001). Construction and functional evaluation of a single-chain antibody fragment that neutralizes toxin AahI from the venom of the scorpion Androctonus australis hector. Eur. J. Biochem. 268:694-702.
100. Andreotti P E, Ludwig G V, Peruski A H, et al. (2003). Immunoassay of infectious agents. Biotechn. 35:850-859.
101. Payne W J, Jr, Marshall D L, Shockley R K, et al. (1988). Clinical laboratory applications of monoclonal antibodies. Clin. Microbiol. Rev. 1:313-329.
102. Arens M Q, Mundy L M, Amsterdam D, et al. (2005). Preclinical and clinical performance of the Efoora test, a rapid test for detection of human immunodeficiency virusspecific antibodies. J. Clin. Microbiol. 43:2399-2406.
103. Walker M, Redelman D (2004). Detection of Cryptosporidium parvum in soil extracts. Appl. Environ. Microbiol. 70:1827-1829.
104. Matsubayashi M, Kimata I, Iseki M, et al. (2005). Cross-reactivities with Cryptosporidium spp. by chicken monoclonal antibodies that recognize avian Eimeria spp. Vet. Parasitol. 10:47-57.
105. Casadevall A, Pirofski L A (2001). Adjunctive immune therapy for fungal infections. Clin. Infect. Dis. 33:1048-1056.
106. Casadevall A, Dadachova E, Pirofski L A (2004). Passive antibody therapy for infectious diseases. Nature Rev. Microbiol. 2:695-703.
107. Casadevall A, Pirofski L A (2004). New concepts in antibody-mediated immunity. Infect. Immun. 72:6191-6196.
108. Cenci E, Bistoni F, Mencacci A, et al. (2004). A synthetic peptide as a novel anticryptococcal agent. Cell Microbiol. 6:953-961.
109. Crabb J H (1998). Antibody-based immunotherapy of cryptosporidiosis. Adv. Parasitol. 40:121-149.
110. Hassani M, Patel M C, Pirofski L A (2004). Vaccines for the prevention of diseases caused by potential bioweapons. Clin. Immunol. 111:1-15.
111. Hengel H, Masihi K N (2003). Combinatorial immunotherapies for infectious diseases. Int. Immunopharmacol. 3:1159-1167.
112. Keller M A, Stiehm E R (2000). Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13:602-614.
113. Berghman L R, Abi-Ghanem D, Waghela S D, et al. (2005). Antibodies: an alternative for antibiotics? Poult. Sci. 84:660-666.
114. Casadevall A (2003). Antibody-mediated immunity against intracellular pathogens:two-dimensional thinking comes full circle. Infect. Immun. 71:4225-4228.
115. Joiner K A, Dubremetz JF (1993). Toxoplasma gondii: a protozoan for the nineties. Infect. Immun. 61:1169-1172.
116. Nardin E H, Nussenzweig R S (1993). T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annu. Rev. Immunol. 11:687-727.
117. Brekke O H, Løset G A (2003). New technologies in therapeutic antibody development. Curr. Opin. Pharmacol. 3:544-550.
118. Casadevall A (2004). The methodology for determining the efficacy of antibodymediated immunity. J. Immunol. Meth. 291:1-10.
119. Chester K A, Hawkins R E (1995). Clinical issues in antibody design. Trends Biotechnol. 13:294-300.
120. Wild M A, Xin H, Maruyama T, et al. (2003). Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nature Biotechnol. 21:1305-1306.
121. Beninati C, Arseni S, Mancuso G, et al. (2004). Protective immunization against group B meningococci using anti-idiotypic mimics of the capsular polysaccharide. J. Immunol. 172:2461-2468.
122. Magliani W, Conti S, Salati A, et al. (2003). Biotechnological approaches to the production of idiotypic vaccines and antiidiotypic antibiotics. Curr. Pharm. Biotechnol. 4:91-97.
123. Polonelli L, Magliani W, Conti S, et al. (2003). Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect. Immun. 71:6205-6212.
124. Matthews R C, Rigg G, Hodgetts S, et al. (2003). Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother. 47:2208-2216.
125. Peschen D, Li H P, Fischer R, et al. (2004). Fusion proteins comprising a Fusariumspecific antibody linked to antifungal peptides protect plants against a fungal pathogen. Nature Biotechnol. 22:732-738.
126. Li F, Dluzewski A, Coley A M, et al. (2002). Phage-displayed peptides bind to the malarial protein apical membrane antigen-1 and inhibit the merozoite invasion of host erythrocytes. J. Biol. Chem. 277:50303-50310.
127. Vukovic P, Chen K, Qin Liu X, et al. (2002). Single-chain antibodies produced by phage display against the C-terminal 19 kDa region of merozoite surface protein-1 of Plasmodium yoelii reduce parasite growth following challenge. Vaccine. 20:2826-2835.
128. Yoshida S, Matsuoka H, Luo E, et al. (1999). A single-chain antibody fragment specific for the Plasmodium berghei ookinete protein Pbs21 confers transmission blockade in the mosquito midgut. Mol. Biochem. Parasitol. 104:195-204.
129. Villani M E, Roggero P, Bitti O, et al. (2005). Immunomodulation of cucumber mosaic virus infection by intrabodies selected in vitro from a stable single-framework phage display library. Plant Mol. Biol. 58:305-316.
130. Kim Y J, Lebreton F, Kaiser C, et al. (2004). Isolation of foot-and-mouth disease virus specific bovine antibody fragments from phage display libraries. J. Immunol. Meth. 286:155-166.
131. De Logu A, Williamson R A, Rozenshteyn R, et al. (1998). Characterization of a type-common human recombinant monoclonal antibody to herpes simplex virus with high therapeutic potential. J. Clin. Microbiol. 36:3198-3204.
132. Shaheen F, Duan L, Zhu M, et al. (1996). Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle. J. Virol. 70:3392-3400.
133. Goncalves J, Silva F, Freitas-Vieira A, et al. (2002). Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication. J. Biol. Chem. 277:32036-32045.
134. Wu S C, Lin Y J, Chou J W, et al. (2004). Construction and characterization of a Fab recombinant protein for Japanese encephalitis virus neutralization. Vaccine. 23:163-171.
135. de Carvalho Nicacio C, Williamson R A, Parren P W, et al. (2002). Neutralizing human Fab fragments against measles virus recovered by phage display. J. Virol. 76:251-258.
136. Ray K, Embleton M J, Jailkhani B L, et al. (2001). Selection of single chain variable fragments (scFv) against the glycoprotein antigen of the rabies virus from a human synthetic scFv phage display library and their fusion with the Fc region of human IgG1. Clin. Exp. Immunol. 125:94-101.
137. Higo-Moriguchi K, Akahori Y, Iba Y, et al. (2004). Isolation of human monoclonal antibodies that neutralize human rotavirus. J. Virol. 78:3325-3332.
138. Kausmally L, Waalen K, Lobersli I, et al. (2004). Neutralizing human antibodies to varicella-zoster virus (VZV) derived from a VZV patient recombinant antibody library. J. Gen. Virol. 85:3493-3500.
139. Donofrio G, Heppner F L, Polymenidou M, et al. (2005). Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J. Virol. 79:8330-8338.
140. Peretz D, Williamson R A, Kaneko K, et al. (2001). Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature. 412:739-743.
141. Riggs M W, Stone A L, Yount P A, et al. (1997). Protective monoclonal antibody defines a circumsporozoite-like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merozoites. J. Immunol. 158:1787-1795.
142. Freedman D J, Tacket C O, Delehanty A, et al. (1998). Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli. J. Infect. Dis. 177:662-667.
143. Tacket C O, Binion S B, Bostwick E, et al. (1992). Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am. J. Trop. Med. Hyg. 47:276-283.
144. Hayden M S, Gilliland L K, Ledbetter J A (1997). Antibody engineering. Curr. Opin. Immunol. 9:201-212.
145. Nabel GJ (2004). Genetic, cellular and immune approaches to disease therapy: past and future. Nature Med. 10:135-141.
146. Griffiths A D, Williams S C, Hartley O, et al. (1994). Isolation of high affinity human antibodies directly from large synthetic repertoires. Embo. J. 13:3245-3260.
147. Montgomery D L, Ulmer J B, Donnelly J J, et al. (1997). DNA vaccines. Pharmacol. Ther. 74:195-205.
148. Rocha C D, Caetano B C, Machado A V, et al. (2004). Recombinant viruses as tools to induce protective cellular immunity against infectious diseases. Int. Microbiol. 7:83-94.
149. Penttila T, Tammiruusu A, Liljestrom P, et al. (2004). DNA immunization followed by a viral vector booster in a Chlamydia pneumoniae mouse model. Vaccine. 22:3386-3394.
150. Hong-Xuan H, Lei C, Cheng-Min W, et al. (2005). Expression of the recombinant fusion protein CP15-23 of Cryptosporidium parvum and its protective test. J. Nanosci. Nanotechnol. 5:1292-1296.
151. Melzer H, Baier K, Felici F, et al. (2003). Humoral immune response against proteophosphoglycan surface antigens of Entamoeba histolytica elicited by immunization with synthetic mimotope peptides. FEMS Immunol. Med. Microbiol. 37:179-183.
152. Gonzalo R M, Rodriguez D, Garcia-Sastre A, et al. (1999). Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Vaccine. 17:887-892.
153. Simon B E, Cornell K A, Clark T R, et al. (2003). DNA vaccination protects mice against challenge with Listeria monocytogenes expressing the hepatitis C virus NS3 protein. Infect. Immun. 71:6372-6380.
154. Sechi L A, Mara L, Cappai P, et al. (2006). Immunization with DNA vaccines encoding different mycobacterial antigens elicits a Th1 type immune response in lambs and protects against Mycobacterium avium subspecies paratuberculosis infection. Vaccine. 3:229-235.
155. Moorthy V S, Pinder M, Reece W H, et al. (2003). Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults. J. Infect. Dis. 188:1239-1244.
156. Xia Y J, Wen W H, Huang W Q, et al. (2005). Development of a phage displayed disulfide-stabilized Fv fragment vaccine against Vibrio anguillarum. Vaccine. 23:3174-3180.
157. Sun J H, Yan Y X, Jiang J, et al. (2005). DNA immunization against very virulent infectious bursal disease virus with VP2-4-3 gene and chicken IL-6 gene. J. Vet. Med. B Infect. Dis. Vet. Public. Health. 52:1-7.
158. Murata K, Garcia-Sastre A, Tsuji M, et al. (1996). Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Cell Immunol. 173:96-107.
159. He H, Zhao B, Liu L, et al. (2004). The humoral and cellular immune responses in mice induced by DNA vaccine expressing the sporozoite surface protein of Cryptosporidium parvum. DNA Cell Biol. 23:335-339.
160. Ivory C, Chadee K (2004). DNA vaccines: designing strategies against parasitic infections. Genet. Vaccines Ther. 2:17.